-
On June 30, Avistone’s independently developed MET inhibitor Vebreltinib received conditional approval from the National Medical Products Administration (NMPA) of China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET amplifi...Read more »
-
On June 30, 2025，HUTCHMED announces that the New Drug Application (NDA) for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastati...Read more »
-
On June 30, the official website of the National Medical Products Administration (NMPA) announced that Anlotinib, a Class 1 new drug developed by Chia Tai Tianqing, has received approval for a new indication in China: combination therapy with chemotherapy for the first-line treatment of patients ...Read more »
-
On June 26, 2025, CARsgen announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudi...Read more »
-
On June 19, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Livzon Pharmaceutical’s LM-108 injection has been proposed for inclusion in the breakthrough therapy designation. The combination of Kefeqibai monoclonal antibody injection (LM-1...Read more »
-
On June 19, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Innovent Biologics’ IBI343 has been proposed for inclusion in the breakthrough therapy designation program, intended for the treatment of locally advanced or metastatic pan...Read more »
-
On June 6, the international medical journal Journal of Hematology & Oncology published the phase I/II study results (KL264-01/MK-2870-001) of the innovative TROP2 ADC sacituzumab tirumotecan (sac-TMT) as monotherapy for unresectable locally advanced or metastatic solid tumors refractory to s...Read more »
-
On June 10, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Trastuzumab Deruxtecan (T-DXd, DS-8201a) is proposed to be granted priority review for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric o...Read more »
-
Recently, Merck & Co., Inc. (Merck) announced that its PD-1 inhibitor, pembrolizumab, has been approved by the National Medical Products Administration (NMPA) of China for use in combination with lenvatinib and transarterial chemoembolization (TACE) for the treatment of patients with unresect...Read more »
-
On June 11, Kelun-Biotech announced that its independently developed TROP2 ADC drug sac-TMT (佳泰莱), in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱”), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Med...Read more »
-
On May 29, the National Medical Products Administration (NMPA) approved the marketing of Zanidatamab, submitted by BeiGene, for the treatment of patients with unresectable locally advanced or metastatic biliary tract cancer (BTC) who have previously received systemic therapy and exhibit high HER2...Read more »
-
On Jun 04, 2025，Akeso announce that the National Medical Products Administration (NMPA) has approved the company’s first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of persistent, recurrent, or metastatic cervical cancer, in combination with platinu...Read more »
Cooperative medical institution of
Beijing Cancer Hospital